Liver Failure - Pipeline Review, H1 2012
Global Markets Direct
January 23, 2012 35 Pages - SKU: GMD6776048
|
|
Liver Failure - Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Liver Failure - Pipeline Review, H1 2012', provides an overview of the Liver Failure therapeutic pipeline. This report provides information on the therapeutic development for Liver Failure, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Failure. 'Liver Failure - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Liver Failure.
- A review of the Liver Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Liver Failure pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Liver Failure.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Liver Failure pipeline depth and focus of Liver Failure therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
|
- Introduction
- Global Markets Direct Report Coverage
- Liver Failure Overview
- Therapeutics Development
- An Overview of Pipeline Products for Liver Failure
- Liver Failure Therapeutics under Development by Companies
- Liver Failure Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Liver Failure Therapeutics - Products under Development by Companies
- Liver Failure Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Liver Failure Therapeutics Development
- Geron Corporation
- Angion Biomedica Corp.
- Liver Failure - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- ANG-1170 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ANG-2864 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- N-Acetylcysteine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Allogenic Bone Marrow Stem Cells Transplant - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- ALF-5755 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Hepatocytes - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Liver Failure Therapeutics - Dormant Products
- Liver Failure - Product Development Milestones
- Featured News & Press Releases
- Sep 21, 2011: Digna Biotech Receives FDA Orphan Drug Status For Cardiotrophin-1 For Acute Liver Failure Treatment
- May 05, 2011: Alfact Innovation Receives Orphan Drug Designation For ALF-5755 From FDA
- Mar 16, 2011: Digna Biotech And Biotecnol Receive Spanish Approval For Phase I Clinical Studies Of Cardiotrophin I
- Mar 10, 2011: Digna Biotech And Biotecnol Announce Spanish Approval For Phase I Clinical study Of Cardiotrophin I
- May 15, 2009: Cardiotrophin-1 Showed To Improve Ssurvival In A Rabbit Model Of Fulminant Hepatic Failure (FHF) Of Viral Origin
- May 06, 2008: University of Edinburgh Human Embryonic Stem Cell Program Awarded UK Grant Funding
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Liver Failure, H1 2012
- Products under Development for Liver Failure - Comparative Analysis, H1 2012
- Number of Products under Development by Companies, H1 2012
- Number of Products under Investigation by Universities/Institutes, H1 2012
- Comparative Analysis by Late Stage Development, H1 2012
- Comparative Analysis by Mid Clinical Stage Development, H1 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Geron Corporation, H1 2012
- Angion Biomedica Corp., H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Liver Failure Therapeutics - Dormant Products
- List of Figures
- Number of Products under Development for Liver Failure, H1 2012
- Products under Development for Liver Failure - Comparative Analysis, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Late Stage Products, H1 2012
- Mid Clinical Stage Products, H1 2012
- Discovery and Pre-Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
Share this report
Other tasks Related Markets Drug Discovery Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
